MedTrace Logo

[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

NCT05499637 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-05-11

No results posted yet for this study

Summary

Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.

Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of \[68Ga\]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.

The identification of a correlation between \[68Ga\]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.

Conditions

  • Acute Cellular Graft Rejection
  • Cardiac Sarcoidosis
  • Myocarditis Due to Drug

Interventions

DRUG

[68Ga]Ga-PentixaFor PET/CT

\[68Ga\]Ga-PentixaFor PET/CT

Sponsors & Collaborators

  • John O. Prior

    lead OTHER

Principal Investigators

  • John O Prior, MD, PhD · University of Lausanne Hospitals

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2026-12-31
Completion
2027-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05499637 on ClinicalTrials.gov